15,170 Shares in Innoviva, Inc. (NASDAQ:INVA) Acquired by Intech Investment Management LLC

Intech Investment Management LLC purchased a new position in shares of Innoviva, Inc. (NASDAQ:INVA) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 15,170 shares of the biotechnology company’s stock, valued at approximately $249,000.

Several other institutional investors have also made changes to their positions in INVA. EdgeRock Capital LLC acquired a new stake in shares of Innoviva during the second quarter worth approximately $31,000. Bessemer Group Inc. boosted its holdings in shares of Innoviva by 333.5% during the first quarter. Bessemer Group Inc. now owns 2,211 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 1,701 shares during the period. Innealta Capital LLC acquired a new stake in shares of Innoviva during the second quarter worth approximately $33,000. GAMMA Investing LLC boosted its holdings in shares of Innoviva by 124.0% during the first quarter. GAMMA Investing LLC now owns 2,262 shares of the biotechnology company’s stock worth $34,000 after purchasing an additional 1,252 shares during the period. Finally, SG Americas Securities LLC acquired a new stake in shares of Innoviva during the first quarter worth approximately $138,000. 99.12% of the stock is currently owned by institutional investors and hedge funds.

Innoviva Price Performance

Shares of INVA opened at $19.32 on Friday. The firm has a market cap of $1.21 billion, a PE ratio of 8.70 and a beta of 0.57. The firm’s 50 day moving average price is $18.90 and its 200 day moving average price is $16.77. The company has a debt-to-equity ratio of 0.67, a quick ratio of 11.40 and a current ratio of 12.70. Innoviva, Inc. has a twelve month low of $12.22 and a twelve month high of $20.19.

Innoviva (NASDAQ:INVA) last issued its quarterly earnings data on Wednesday, July 31st. The biotechnology company reported $0.68 earnings per share for the quarter. Innoviva had a net margin of 44.00% and a return on equity of 33.26%. The firm had revenue of $99.90 million for the quarter. As a group, research analysts expect that Innoviva, Inc. will post 0.5 EPS for the current fiscal year.

Analysts Set New Price Targets

INVA has been the subject of several research reports. Cantor Fitzgerald restated an “overweight” rating on shares of Innoviva in a report on Tuesday, July 30th. StockNews.com lowered shares of Innoviva from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, August 6th.

Innoviva Company Profile

Innoviva, Inc engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company’s products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.